Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 130

1.

Ventriculo-arterial coupling detects occult RV dysfunction in chronic thromboembolic pulmonary vascular disease.

Axell RG, Messer SJ, White PA, McCabe C, Priest A, Statopoulou T, Drozdzynska M, Viscasillas J, Hinchy EC, Hampton-Till J, Alibhai HI, Morrell N, Pepke-Zaba J, Large SR, Hoole SP.

Physiol Rep. 2017 Apr;5(7). pii: e13227. doi: 10.14814/phy2.13227.

2.

Medical management of chronic thromboembolic pulmonary hypertension.

Pepke-Zaba J, Ghofrani HA, Hoeper MM.

Eur Respir Rev. 2017 Mar 29;26(143). pii: 160107. doi: 10.1183/16000617.0107-2016. Print 2017 Mar 31. Review.

3.

Survival in portopulmonary hypertension: Outcomes of the United Kingdom National Pulmonary Arterial Hypertension Registry.

Sithamparanathan S, Nair A, Thirugnanasothy L, Coghlan JG, Condliffe R, Dimopoulos K, Elliot CA, Fisher AJ, Gaine S, Gibbs JSR, Gatzoulis MA, E Handler C, Howard LS, Johnson M, Kiely DG, Lordan JL, Peacock AJ, Pepke-Zaba J, Schreiber BE, Sheares KKK, Wort SJ, Corris PA; National Pulmonary Hypertension Service Research Collaboration of the United Kingdom and Ireland.

J Heart Lung Transplant. 2017 Jul;36(7):770-779. doi: 10.1016/j.healun.2016.12.014. Epub 2016 Dec 31.

PMID:
28190786
4.

Comprehensive Rare Variant Analysis via Whole-Genome Sequencing to Determine the Molecular Pathology of Inherited Retinal Disease.

Carss KJ, Arno G, Erwood M, Stephens J, Sanchis-Juan A, Hull S, Megy K, Grozeva D, Dewhurst E, Malka S, Plagnol V, Penkett C, Stirrups K, Rizzo R, Wright G, Josifova D, Bitner-Glindzicz M, Scott RH, Clement E, Allen L, Armstrong R, Brady AF, Carmichael J, Chitre M, Henderson RH, Hurst J, MacLaren RE, Murphy E, Paterson J, Rosser E, Thompson DA, Wakeling E, Ouwehand WH, Michaelides M, Moore AT; NIHR-BioResource Rare Diseases Consortium, Webster AR, Raymond FL.

Am J Hum Genet. 2017 Jan 5;100(1):75-90. doi: 10.1016/j.ajhg.2016.12.003. Epub 2016 Dec 29.

5.

Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension.

Rhodes CJ, Ghataorhe P, Wharton J, Rue-Albrecht KC, Hadinnapola C, Watson G, Bleda M, Haimel M, Coghlan G, Corris PA, Howard LS, Kiely DG, Peacock AJ, Pepke-Zaba J, Toshner MR, Wort SJ, Gibbs JS, Lawrie A, Gräf S, Morrell NW, Wilkins MR.

Circulation. 2017 Jan 31;135(5):460-475. doi: 10.1161/CIRCULATIONAHA.116.024602. Epub 2016 Nov 21.

7.

Contemporary diagnosis and management of pulmonary hypertension.

Cannon JE, Pepke-Zaba J.

Heart. 2016 Oct 15;102(20):1680-91. doi: 10.1136/heartjnl-2015-307996. No abstract available.

PMID:
27679806
8.

Medical Therapy in Chronic Thromboembolic Pulmonary Hypertension.

Pepke-Zaba J, Jais X, Channick R.

Ann Am Thorac Soc. 2016 Jul;13 Suppl 3:S248-54. doi: 10.1513/AnnalsATS.201512-802AS.

PMID:
27571006
9.

Chronic Thromboembolic Pulmonary Hypertension. The Journey from a Curiosity to a Cure.

Auger WR, Mandel J, Pepke-Zaba J.

Ann Am Thorac Soc. 2016 Jul;13 Suppl 3:S197-200. doi: 10.1513/AnnalsATS.201509-618AS.

PMID:
27571000
10.

Neutrophil Extracellular Traps Promote Angiogenesis: Evidence From Vascular Pathology in Pulmonary Hypertension.

Aldabbous L, Abdul-Salam V, McKinnon T, Duluc L, Pepke-Zaba J, Southwood M, Ainscough AJ, Hadinnapola C, Wilkins MR, Toshner M, Wojciak-Stothard B.

Arterioscler Thromb Vasc Biol. 2016 Oct;36(10):2078-87. doi: 10.1161/ATVBAHA.116.307634. Epub 2016 Jul 28.

PMID:
27470511
11.

Pre-Capillary, Combined, and Post-Capillary Pulmonary Hypertension: A Pathophysiological Continuum.

Opitz CF, Hoeper MM, Gibbs JS, Kaemmerer H, Pepke-Zaba J, Coghlan JG, Scelsi L, D'Alto M, Olsson KM, Ulrich S, Scholtz W, Schulz U, Grünig E, Vizza CD, Staehler G, Bruch L, Huscher D, Pittrow D, Rosenkranz S.

J Am Coll Cardiol. 2016 Jul 26;68(4):368-78. doi: 10.1016/j.jacc.2016.05.047.

12.

Exercise physiological responses to drug treatments in chronic thromboembolic pulmonary hypertension.

Charalampopoulos A, Gibbs JS, Davies RJ, Gin-Sing W, Murphy K, Sheares KK, Pepke-Zaba J, Jenkins DP, Howard LS.

J Appl Physiol (1985). 2016 Sep 1;121(3):623-8. doi: 10.1152/japplphysiol.00087.2016. Epub 2016 Jul 14.

PMID:
27418685
13.

Quality of life in patients with chronic thromboembolic pulmonary hypertension.

Mathai SC, Ghofrani HA, Mayer E, Pepke-Zaba J, Nikkho S, Simonneau G.

Eur Respir J. 2016 Aug;48(2):526-37. doi: 10.1183/13993003.01626-2015. Epub 2016 Apr 13. Review.

14.

Dynamic Risk Stratification of Patient Long-Term Outcome After Pulmonary Endarterectomy: Results From the United Kingdom National Cohort.

Cannon JE, Su L, Kiely DG, Page K, Toshner M, Swietlik E, Treacy C, Ponnaberanam A, Condliffe R, Sheares K, Taboada D, Dunning J, Tsui S, Ng C, Gopalan D, Screaton N, Elliot C, Gibbs S, Howard L, Corris P, Lordan J, Johnson M, Peacock A, MacKenzie-Ross R, Schreiber B, Coghlan G, Dimopoulos K, Wort SJ, Gaine S, Moledina S, Jenkins DP, Pepke-Zaba J.

Circulation. 2016 May 3;133(18):1761-71. doi: 10.1161/CIRCULATIONAHA.115.019470. Epub 2016 Apr 6.

15.

Pulmonary endarterectomy is effective and safe in patients with haemoglobinopathies and abnormal red blood cells: the Papworth experience.

Mahesh B, Besser M, Ravaglioli A, Pepke-Zaba J, Martinez G, Klein A, Ng C, Tsui S, Dunning J, Jenkins DP.

Eur J Cardiothorac Surg. 2016 Sep;50(3):537-41. doi: 10.1093/ejcts/ezw062. Epub 2016 Mar 17.

PMID:
26987879
16.

Endothelin ETA receptors predominate in chronic thromboembolic pulmonary hypertension.

Southwood M, MacKenzie Ross RV, Kuc RE, Hagan G, Sheares KK, Jenkins DP, Goddard M, Davenport AP, Pepke-Zaba J.

Life Sci. 2016 Aug 15;159:104-110. doi: 10.1016/j.lfs.2016.02.036. Epub 2016 Feb 10.

17.

Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension: Results From an International Prospective Registry.

Delcroix M, Lang I, Pepke-Zaba J, Jansa P, D'Armini AM, Snijder R, Bresser P, Torbicki A, Mellemkjaer S, Lewczuk J, Simkova I, Barberà JA, de Perrot M, Hoeper MM, Gaine S, Speich R, Gomez-Sanchez MA, Kovacs G, Jaïs X, Ambroz D, Treacy C, Morsolini M, Jenkins D, Lindner J, Dartevelle P, Mayer E, Simonneau G.

Circulation. 2016 Mar 1;133(9):859-71. doi: 10.1161/CIRCULATIONAHA.115.016522. Epub 2016 Jan 29.

18.

Selexipag for the Treatment of Pulmonary Arterial Hypertension.

Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV; GRIPHON Investigators.

N Engl J Med. 2015 Dec 24;373(26):2522-33. doi: 10.1056/NEJMoa1503184.

19.

Developments in pulmonary arterial hypertension-targeted therapy for chronic thromboembolic pulmonary hypertension.

Hadinnapola C, Pepke-Zaba J.

Expert Rev Respir Med. 2015 Oct;9(5):559-69. doi: 10.1586/17476348.2015.1085805. Review.

PMID:
26366805
20.

Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.

Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery JL, Grünig E, Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ; AMBITION Investigators.

N Engl J Med. 2015 Aug 27;373(9):834-44. doi: 10.1056/NEJMoa1413687.

Supplemental Content

Loading ...
Support Center